Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness
NCT04258462Phase 2Active, not recruiting
- Start
- Jan 2019
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [1-13C]pyruvate in kidney neoplasm (2 arms). Primary endpoints: HP 13C pyruvate-to-lactate conversion measured by peak lactate/pyruvate ratio at 12 months, HP 13C pyruvate-to-lactate conversion measured by lactate/pyruvate area under curve (AUC) at 12 months and 1 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
kidney neoplasm
Beyond the preview
Go deeper on NCT04258462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258462.